About bicycle therapeutics plc - BCYC
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC At a Glance
Bicycle Therapeutics Plc
Granta Park Great Abington
Cambridge, Cambridgeshire CB21 6GS
| Phone | 44-1223-261503 | Revenue | 72.76M | |
| Industry | Pharmaceuticals: Major | Net Income | -219,471,681.21 | |
| Sector | Health Technology | 2025 Sales Growth | 106.166% | |
| Fiscal Year-end | 12 / 2026 | Employees | 288 | |
| View SEC Filings |
BCYC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.742 |
| Price to Book Ratio | 0.805 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.436 |
| Enterprise Value to Sales | -1.658 |
| Total Debt to Enterprise Value | -0.145 |
BCYC Efficiency
| Revenue/Employee | 252,623.695 |
| Income Per Employee | -762,054.449 |
| Receivables Turnover | 2.044 |
| Total Asset Turnover | 0.087 |
BCYC Liquidity
| Current Ratio | 11.984 |
| Quick Ratio | 11.984 |
| Cash Ratio | 11.032 |
BCYC Profitability
| Gross Margin | 91.153 |
| Operating Margin | -389.384 |
| Pretax Margin | -349.555 |
| Net Margin | -301.656 |
| Return on Assets | -26.214 |
| Return on Equity | -31.285 |
| Return on Total Capital | -34.976 |
| Return on Invested Capital | -30.873 |
BCYC Capital Structure
| Total Debt to Total Equity | 2.872 |
| Total Debt to Total Capital | 2.792 |
| Total Debt to Total Assets | 2.442 |
| Long-Term Debt to Equity | 2.421 |
| Long-Term Debt to Total Capital | 2.353 |